Patients meeting the selection criteria are currently being pre-screened for entry into the Phase 2 Depression trialEthics and clinical trials…
Trial met primary endpoint with the 60 mcg dose, with BXCL501 demonstrating a statistically significant 39% greater reduction in PEC…
San Francisco, CA, April 14, 2023 (GLOBE NEWSWIRE) -- With the promise of revolutionary technologies and patient-centered care, OMED AI…
Arlington, VA, April 13, 2023 (GLOBE NEWSWIRE) -- If you’re wondering how artificial intelligence (AI) will affect your healthcare institution,…
Enable Cloud Platform trained on high plex spatial imaging datasets across 20,000 samples run on the PhenoCycler® SystemCommercial launch at…
BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay…
Abu Dhabi-based collaboration to focus on accelerating the development of new personalized medications using AIABU DHABI, United Arab Emirates, Jan.…
Results demonstrate encouraging response rate of BXCL701 plus KEYTRUDA® (pembrolizumab) in patients with SCNC Full data will be presented at…
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia…
HONG KONG, Dec. 05, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,…